GHRH and GHRP Research Peptides, Side by Side

The short version

Aus Peptide is a reading desk, not a store. It exists to lay out, in plain language and with citations, what the published research literature actually says about three peptides connected — more or less closely — to the growth hormone (GH) axis: CJC-1295/Ipamorelin, MOTS-c, and sermorelin.

Two of the three work the way you'd expect a 'growth hormone peptide' to work: they act directly on the pituitary gland to nudge it into releasing more of its own GH. Sermorelin does this alone. CJC-1295/Ipamorelin does it through two different receptors at once. MOTS-c is the outlier — a mitochondrial-derived peptide that works inside cells on energy metabolism and never touches the pituitary. It's included because it circulates in the same research conversation, not because the mechanism matches.

Nothing here is a recommended dose or a treatment plan. Every claim is tied to a study, and every study is described the way it was actually run.

What is the Growth Hormone Axis?

The growth hormone axis is the feedback loop that governs how much growth hormone (GH) the body makes and releases. It starts in the hypothalamus, which sends growth hormone-releasing hormone (GHRH) down to the pituitary gland. GHRH binds the GHRH receptor on cells called somatotrophs, which respond by making and releasing GH in pulses — mostly overnight, during deep sleep. GH then travels to the liver and other tissues, where it stimulates production of insulin-like growth factor 1 (IGF-1), the molecule that carries out much of GH's downstream work on muscle, bone, and metabolism.

A second entry point exists: the ghrelin receptor (GHS-R1a), best known as the 'hunger hormone' receptor, also sits on those same pituitary cells and, when activated, triggers its own GH pulse through a separate intracellular pathway. Peptides that mimic GHRH are called GHRH analogues; peptides that mimic ghrelin at that receptor are called growth hormone-releasing peptides (GHRPs) or secretagogues. Sermorelin is a GHRH analogue. Ipamorelin is a GHRP. CJC-1295 is a longer-acting GHRH analogue. Combining a GHRH analogue with a GHRP is the basis of the 'stack' logic behind CJC-1295/Ipamorelin ^[5].

GHRH and GHRP, side by side — and the mitochondrial outlier

This desk's organizing frame is deliberately narrow: GHRH and GHRP research peptides, side by side. Sermorelin is the reference GHRH analogue — literally the first 29 amino acids of the natural 44-residue hormone, the shortest fragment known to retain full activity at the GHRH receptor ^[11]. CJC-1295/Ipamorelin pairs a chemically extended GHRH analogue with ipamorelin, a selective GHRP, on the reasoning that hitting the GHRH receptor and the ghrelin receptor together produces a bigger GH pulse than either alone — a synergy documented at the receptor level in transfected cells, though never studied as a fixed combination in a controlled human trial ^[5].

MOTS-c doesn't fit this frame mechanistically, and we say so plainly rather than stretch a connection that isn't there. It's encoded inside the mitochondrial genome and acts through AMPK and casein kinase 2 to influence how muscle cells handle glucose and stress — a metabolic story, not a pituitary one ^[6][8]. It sits on this desk because people researching GH-axis peptides for body composition and healthy aging frequently research MOTS-c in the same breath, not because the two mechanisms overlap.

What are research peptides?

Peptides are short chains of amino acids — the same building blocks as proteins, just far smaller. All three compounds on this desk are described by manufacturers and vendors as research chemicals: none is approved by the FDA for the uses most commonly discussed in research-use communities today. Sermorelin previously held FDA approval under a now-discontinued brand for a narrow pediatric growth-deficiency indication, and was withdrawn from the market for commercial reasons in 2008, not for a safety or efficacy failure; it is available today only through compounding pharmacies. CJC-1295 and ipamorelin have never held FDA approval for any human indication. MOTS-c has never been tested in a human clinical trial for any indication at all.

Material sold as any of these three compounds outside a regulated pharmacy supply chain is not independently verified for identity, purity, or sterility, and this desk reports that fact wherever it's relevant rather than treating it as a footnote.